Mariam A Malallah1, Tariq F Al-Shaiji. 1. Division of Urology, Department of Surgery, Al-Adan Hospital, Kuwait, Kuwait, drmalallah@icloud.com.
Abstract
INTRODUCTION AND HYPOTHESIS: Treatment escalation from conservative directly to surgical in the management of pure stress urinary incontinence (SUI) reveals a gap for effective pharmacological treatments. The introduction of a drug therapy would fill this gap and widen the treatment options. Nevertheless, various pharmaceutical agents have been used off-label and are being investigated and becoming more widely available. In this review, we examined the latest published data regarding pharmacotherapy used in the treatment of SUI. METHODS: We performed a literature review to evaluate the relevant studies pertaining to any pharmacotherapy used in the management of SUI, examining the English language literature. RESULTS: Currently, no drug exists that is approved by the food and drug administration for the management of SUI. A few oral pharmacological agents are occasionally used off-label. Lack of proven efficacy and high incidence of bothersome side effects of these agents limit their use. Duloxetine, a serotonin norepinephrine reuptake inhibitor, represents a major therapeutic advance for the treatment of SUI based on findings from a number of controlled clinical trials. CONCLUSIONS: Several pharmacological agents have been used off-label and investigated for safety and efficacy, but none has demonstrated sufficient effectiveness to receive widespread verification for its use in the treatment of SUI.
INTRODUCTION AND HYPOTHESIS: Treatment escalation from conservative directly to surgical in the management of pure stress urinary incontinence (SUI) reveals a gap for effective pharmacological treatments. The introduction of a drug therapy would fill this gap and widen the treatment options. Nevertheless, various pharmaceutical agents have been used off-label and are being investigated and becoming more widely available. In this review, we examined the latest published data regarding pharmacotherapy used in the treatment of SUI. METHODS: We performed a literature review to evaluate the relevant studies pertaining to any pharmacotherapy used in the management of SUI, examining the English language literature. RESULTS: Currently, no drug exists that is approved by the food and drug administration for the management of SUI. A few oral pharmacological agents are occasionally used off-label. Lack of proven efficacy and high incidence of bothersome side effects of these agents limit their use. Duloxetine, a serotonin norepinephrine reuptake inhibitor, represents a major therapeutic advance for the treatment of SUI based on findings from a number of controlled clinical trials. CONCLUSIONS: Several pharmacological agents have been used off-label and investigated for safety and efficacy, but none has demonstrated sufficient effectiveness to receive widespread verification for its use in the treatment of SUI.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip van Kerrebroeck; Arne Victor; Alan Wein Journal: Neurourol Urodyn Date: 2002 Impact factor: 2.696
Authors: Bernard T Haylen; Dirk de Ridder; Robert M Freeman; Steven E Swift; Bary Berghmans; Joseph Lee; Ash Monga; Eckhard Petri; Diaa E Rizk; Peter K Sand; Gabriel N Schaer Journal: Int Urogynecol J Date: 2009-11-25 Impact factor: 2.894
Authors: Philip van Kerrebroeck; Paul Abrams; Rainer Lange; Mark Slack; Jean-Jacques Wyndaele; Ilker Yalcin; Richard C Bump Journal: BJOG Date: 2004-03 Impact factor: 6.531
Authors: Tejs Jansen; Lotte C G Hoegberg; Thomas Eriksen; Kim P Dalhoff; Bo Belhage; Sys S Johansen Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-06-11 Impact factor: 3.000
Authors: Rıza Dur; İltaç Akkurt; Bora Coşkun; Gamze Dur; Buğra Çoşkun; Mehmet Ünsal; Ahmet Akın Sivaslıoğlu Journal: Turk J Obstet Gynecol Date: 2019-10-10